Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer By Ogkologos - March 31, 2026 226 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATOMIC study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other... September 4, 2018 The future of research: meet three of our scientists working on... December 13, 2022 Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant... March 8, 2023 FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer November 20, 2023 Load more HOT NEWS FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate... Tips from Your Cancer Care Team – Coping with Treatment During... FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... This Breast Cancer Patient Is Using Boudoir Photography to Reclaim Her...
